Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 Universal CAR T Cells in Refractory SLE
NCT06691152Phase 1Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Oct 2024
- Primary completion
- Sep 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cd19 universal car-t cells in systemic lupus erythematosus (SLE), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Adverse events related to CD19 universal CAR-T cells at 3 months. Started Oct 2024; status: recruiting.
02
Drugs
cd19 universal car-t cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06691152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06691152.